Biotech Values

[bladerunner1717]

CCXI proposed public offering.


https://finance.yahoo.com/news/chemocentryx-announces-proposed-public-offering-200851978.html


Bladerunner





















































Mail
Finance Home
Premium - Try it free
WatchlistsMy PortfolioScreenersPremiumMarketsNews
Personal FinanceVideosIndustriesTech
U.S. markets closed
S&P 500
3,190.14
-17.04(-0.53%)
Dow 30
26,989.99
-282.31(-1.04%)
Nasdaq
10,020.35
+66.59(+0.67%)
Russell 2000
1,467.39
-39.66(-2.63%)
Crude Oil
39.06
-0.54(-1.36%)

My Portfolios/Contest 2020People Also Watch:AFMDINOPTNTRVNTGTX
Link BrokerCreate PortfolioPrintImportExportSettings
$134,757.85
Day Gain-1,531.72 (-1.12%)
Total Gain+34,814.80 (+34.83%)
Annual Performance
^GSPCPortfolio
Risk Profile
Low
High
Moderately Aggressive
Valuation
8Overvalued
Diversity
100%Healthcare
Summary
My Holdings
Fundamentals
Performance
Characteristics
Risk Analysis
Performance
New View
Create New View
Add SymbolReorderEdit ViewDelete ViewCurrency in USD
Symbol Prev Close Open Last Price Change Chg % High Low Volume Avg Vol (10day) 52-Wk High 52-Wk Low Market Cap Shares Out 50-DMA 200-DMA Shares Cost / Share Day Chg Total Chg Total Chg % Day Chg % Annualized Gain
CCXI 62.48 62.50 60.25 -2.23 -3.57% 64.31 59.92 279,239 529,000 64.31 6.16 3.727B 61.854M 56.18 44.30 278.164 35.95 -620.31 +6,759.39 +67.59% -3.57% -
CHMA 6.47 6.60 6.21 -0.26 -4.02% 6.60 6.21 255,061 291,071 9.25 2.88 262.468M 42.265M 5.71 4.89 2109.704 4.74 -548.52 +3,101.26 +31.01% -4.02% -
MEIP 3.8200 3.8700 3.9000 +0.0800 +2.09% 4.0200 3.8050 1.235M 2.718M 4.3300 0.7200 413.396M 105.999M 2.90 2.20 8695.652 2.3000 +695.6536 +13,913.0440 +69.5652% +2.0942% -
MGTA 10.56 10.61 10.40 -0.16 -1.47% 10.82 10.09 115,223 175,142 16.87 5.76 410.637M 39.589M 9.26 10.98 334.896 14.76 -51.91 -1,460.15 -29.54% -1.47% -
NERV 3.6600 3.7200 3.6200 -0.0400 -1.09% 3.8500 3.6000 3.262M 9.563M 15.2150 1.8100 141.973M 39.219M 9.42 7.72 2652.519 7.5400 -106.1013 -10,397.8748 -51.9894% -1.0929% -
OTIC 3.1100 3.0800 3.3000 +0.1900 +6.11% 3.3200 2.9400 243,568 144,785 4.1800 1.5300 101.864M 30.868M 2.48 2.74 2506.266 3.9900 +476.1907 -1,729.3237 -17.2932% +6.1093% -
TRIL 8.11 8.25 7.90 -0.21 -2.59% 8.28 7.76 1.284M 2.048M 8.45 0.24 657.189M 83.436M 6.09 3.81 3968.254 1.26 -833.33 +26,349.21 +526.98% -2.59% -
XENE 12.47 12.47 12.11 -0.36 -2.89% 12.88 11.75 372,045 408,342 18.45 7.00 423.536M 34.974M 13.04 13.54 1509.434 13.25 -543.40 -1,720.76 -8.60% -2.89% -
Portfolio News
CCXI
GlobeNewswire • 2 hours ago
ChemoCentryx Announces Proposed Public Offering of Common Stock
OTIC
GlobeNewswire • 11 hours ago
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
TRIL
Investopedia • yesterday
Top Biotech Stocks for Q3 2020
MGTA
Business Wire • 2 days ago
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences
OTIC
GlobeNewswire • 2 days ago
Otonomy to Host Pipeline Program Update Conference Call and Webcast
XENE
Insider Monkey • 3 days ago
Hedge Funds Aren’t Done Buying Xenon Pharmaceuticals Inc (XENE)
NERV
Zacks • 5 days ago
Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session
MGTA
Business Wire • 5 days ago
Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases
CHMA
Thomson Reuters StreetEvents • 6 days ago
Edited Transcript of CHMA earnings conference call or presentation 7-May-20 9:00pm GMT
CCXI
GlobeNewswire • 7 days ago
ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses
MEIP
Simply Wall St. • 7 days ago
What You Need To Know About The MEI Pharma, Inc. (NASDAQ:MEIP) Analyst Downgrade Today
NERV
Zacks • 8 days ago
How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry
XENE
GlobeNewswire • 9 days ago
Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
NERV
Motley Fool • 9 days ago
Why Minerva Neurosciences Is Heading Higher Today
XENE
Simply Wall St. • 9 days ago
News Flash: Analysts Just Made A Sizeable Upgrade To Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Forecasts
OTIC
TipRanks • 9 days ago
3 “Strong Buy” Biotech Stocks Under $5 With Major Catalysts Approaching
NERV
GlobeNewswire • 9 days ago
REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
TRIL
Bloomberg • 9 days ago
Cancer Summit Presses Toward Treatments in Covid’s Shadow
NERV
SmarterAnalyst • 10 days ago
Minerva Shares Tank 72% As Schizophrenia Drug Misses Trial Goals
NERV
Motley Fool • 12 days ago
Here's Why Minerva Neurosciences Collapsed Today
CCXI
Investopedia • 12 days ago
Top Small Cap Stocks for June 2020
NERV
TheStreet.com • 12 days ago
Minerva Schizophrenia-Drug Trial Misses Key Endpoints
TRIL
Benzinga • 12 days ago
Why Trillium Therapeutics Is Trading Higher Today
NERV
MarketWatch • 12 days ago
Minerva Neurosciences' stock plummets after schizophrenia treatment disappoints in phase 3 study
NERV
GlobeNewswire • 12 days ago
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
TRIL
GlobeNewswire • 12 days ago
Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program
OTIC
Simply Wall St. • 13 days ago
Health Check: How Prudently Does Otonomy (NASDAQ:OTIC) Use Debt?
MEIP
NERV
Zacks • 14 days ago
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
MEIP
PR Newswire • 14 days ago
MEI Pharma to Present at the Jefferies Virtual Healthcare Conference
NERV
Zacks • 15 days ago
Top Ranked Momentum Stocks to Buy for May 26th
NERV
TipRanks • 15 days ago
Baker Brothers Snap Up These 3 Small-Cap Biotech Stocks
MEIP
PR Newswire • 15 days ago
MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program
NERV
Thomson Reuters StreetEvents • 16 days ago
Edited Transcript of NERV earnings conference call or presentation 4-May-20 12:30pm GMT
XENE
Simply Wall St. • 16 days ago
Earnings Beat: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
XENE
Simply Wall St. • 19 days ago
The Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Is Up 247% And Shareholders Are Boasting About It
XENE
Motley Fool • 19 days ago
Xenon Pharmaceuticals Inc (XENE) Q1 2020 Earnings Call Transcript
XENE
GlobeNewswire • 20 days ago
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
XENE
ACCESSWIRE • 20 days ago
Xenon Pharmaceuticals, Inc. to Host Earnings Call
CCXI
GlobeNewswire • 23 days ago
ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
CCXI
Simply Wall St. • 25 days ago
Analysts Have Just Cut Their ChemoCentryx, Inc. (NASDAQ:CCXI) Revenue Estimates By 11%
Kareem Abdul-Jabbar: ‘The NFL got on the right side of history’
Yahoo Finance
Tesla stock tops $1,000
Yahoo Finance Video
Tesla Soars Past $1,000 After Musk Seizes on Nikola’s Hype
Bloomberg
Gundlach: Retail investor boom during coronavirus crisis 'unnerving,' may be stimulus driven
Yahoo Finance
Stephanie Kelton on her new book 'The Deficit Myth'
Yahoo Finance Video
Gundlach: A 'wave' of layoffs is coming for $100,000/year white-collar jobs
Yahoo Finance
A Booming Airline Business: Shipping Pigs to China in 747 Jumbo Jets
Bloomberg
Allegations of systemic workplace racism took down execs at Bon Appétit, CrossFit and more
Yahoo Finance
Powell: Capping US Treasury yields 'remains an open question'
Yahoo Finance
Fed projects near-zero rates through 2022
Yahoo Finance Video
Fed: No rate hikes likely through 2022, projects 6.5% GDP contraction this year
Yahoo Finance
Zoom earnings, here's what to expect
Yahoo Finance Video
Advertise With Us
© 2020 Verizon Media. All rights reserved.
Data DisclaimerHelpSuggestions
Do not sell my info
Privacy (Updated)About Our AdsTerms (Updated)Sitemap


ChemoCentryx Announces Proposed Public Offering of Common Stock
GlobeNewswire GlobeNewswire•June 10, 2020
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold. SVB Leerink and Piper Sandler are acting as joint bookrunning managers for the offering. All shares of the common stock to be sold in the offering will be offered by ChemoCentryx. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The offering will be made by ChemoCentryx pursuant to a registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission (SEC), which became effective upon filing on June 10, 2020. A preliminary prospectus supplement related to the offering and the accompanying prospectus have been filed with the SEC and are available on the SEC's website located at http://www.sec.gov. These documents may also be obtained from: SVB Leerink LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at [phone], ext. 6218, or by email at [e-mail]; or Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at [phone], or by email at [e-mail].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies.

Bladerunner